Anzeige
Mehr »
Montag, 09.02.2026 - Börsentäglich über 12.000 News
Goldman sieht 15.000 USD bei Kupfer - dieser Explorer ist noch völlig unbekannt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
249 Leser
Artikel bewerten:
(1)

Mural Health and ClinOne Partner to Maximize Patient Experience While Minimizing Site Burden

Strategic partnership integrates next-generation patient support and payment solutions for participants and sites alike

BERWYN, Pa., June 6, 2023 /PRNewswire/ -- Mural Health, a clinical trials technology company that improves the patient and caregiver experience in clinical trials, has today announced a strategic partnership with ClinOne, the leading provider of adaptive clinical trial experience solutions. The move will integrate Mural Link, a next generation patient payments and participant management platform, into ClinOne's patient support and trial management technology. The partnership will further streamline site-level operations and improve the participant journey.

Both companies are using technology to help sponsors overcome the stubborn challenges of drug development, including poor recruitment and retention, by focusing product design on the participant (the end-user). Both companies are also committed to reducing the administrative burden that clinical research sites can experience when sponsors require multiple technology platforms.

Mural Link is an innovative platform that optimizes the participant experience, strategically leveraging next-gen clinical trial payment technology, to continually engage patients and caregivers. Mural Link's novel strategy and market leading technology platform eliminates financial barriers to enrollment, improves site-level operations, and, ultimately, speeds trial execution while improving the quality of the clinical data set. ClinOne shares the same mission, providing a selection of patient engagement solutions, including consent management, medication adherence monitoring, clinic visit ride hailing, a patient and caregiver portal, and e-diaries, in a single platform.

The partnership, announced today, embeds Mural Link into ClinOne's suite of solutions, creating a seamless user experience for patients and sites alike.

"Mural Health offers a truly innovative approach to improving clinical trials," Andrea Valente, CEO at ClinOne, said. "Making participation easy and focusing on efficient study operations align with our goals. We are very excited to partner with the Mural Health team to bring a superior experience to all participants during their clinical trial journey."

Mural Health's Co-Founder and Co-CEO, Sam Whitaker said: "We are thrilled to be working with ClinOne, Andrea and her team share our values and mission. By embedding Mural Link into the ClinOne tech family, we will be able to further streamline site-level operations and empower ClinOne to improve the participant journey for studies its supports."

About Mural Health

Mural Health is a next-generation participant management platform. The Company's Mural Link technology platform is designed to make it easier to participate in clinical trials, thereby improving study operation and the quality of clinical data sets. Mural Link offers next-generation participant payment technology that gives participants the power to choose how they receive payment, eliminates predatory fees related to prepaid debit cards, introduces functionality to help patients arrive at site visits (without incurring a cash expense), empowers communication between participants and site personnel, and captures participant data to predict individuals who are likely to drop-out. The Mural Link platform can be easily deployed to positively improve participant retention and engagement, increase protocol compliance, and increase enrollment rates. Please reach out to us to learn more about or capabilities, www.muralhealth.com or general@muralhealth.com.

About ClinOne

ClinOne connects, informs and empowers patients, caregivers and sites in clinical trials with a true single platform for trial awareness, consent management and patient engagement underpinned with comprehensive data insights tools. Used by more than 80 sponsors, CROs and site networks in 60 countries, our solutions are proven to reduce risk and simplify complex processes for therapeutic areas and patient populations including Oncology, Rare Disease, Pediatrics, the Elderly and CNS. Designed in collaboration with sites and with participants and caregivers in mind, ClinOne features the industry's fastest deployment, cost-efficient scale for trials of all sizes and seamless API integrations to provide the results you need and the experience your patients deserve. Ready to keep patients, sites and study teams active and engaged throughout your clinical trial? Let's get creative at www.clinone.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/mural-health-and-clinone-partner-to-maximize-patient-experience-while-minimizing-site-burden-301843563.html

© 2023 PR Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.